Consensus Ocular Therapeutix, Inc.

Stocks

OCUL

US67576A1007

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-08-28 EDT			5-day change	1st Jan Change
10.36 ^USD	-4.25%		-6.50%	-14.66%

08-18	Ocular Therapeutix, Inc. - Special Call
08-04	Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says	MT

Evolution of the Average Target: Ocular Therapeutix, Inc.

Evolution of the Target Price: Ocular Therapeutix, Inc.

Changes in Analyst Recommendations: Ocular Therapeutix, Inc.

2630ba0.RjsOEgVeFpP1Ug0bnWxaDGVqX_qqLJ-V8Na1RiUrYa8.IU9pJ0QZb_GeZW9yyzU_P1AcKLLiTvz7xrTEcmZcEO0TClZZbhdM3bIdQA~289e2b8e98fa99a5b57e0f141b67f6fa

Analysts' recommendations: Ocular Therapeutix, Inc.

08-04	Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says	MT
06-25	Chardan Raises Price Target on Ocular Therapeutix to $23 From $21, Keeps Buy Rating	MT
05-06	Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says	MT
12-16	RBC Capital Adjusts Ocular Therapeutix Price Target to $24 From $17, Maintains Outperform Rating	MT
25-10-01	Ocular Therapeutix's Axpaxli Drug Trials for Wet AMD Poised for Success, RBC Capital Says	MT
25-09-30	Ocular Therapeutix, Inc. Announces Updates Regarding Its Development Programs for AXPAXLI	CI
25-09-15	Chardan Capital Initiates Ocular Therapeutix at Buy With $21 Price Target	MT
25-04-08	William Blair Initiates Ocular Therapeutix With Outperform Rating	MT
25-03-18	RBC Initiates Ocular Therapeutix at Outperform, Speculative Risk With $17 Price Target	MT
25-03-11	Needham Initiates Ocular Therapeutix at Buy With $15 Price Target	MT
24-10-16	Scotiabank Initiates Ocular Therapeutix at Sector Outperform	MT
24-06-20	TD Cowen Upgrades Ocular Therapeutix to Buy From Hold, Adjusts Price Target to $11 From $7	MT
24-05-31	Piper Sandler Starts Ocular Therapeutix With Overweight Rating, $15 Price Target	MT
24-03-13	HC Wainwright Adjusts Price Target on Ocular Therapeutix to $15 From $12, Keeps Buy Rating	MT
24-03-12	TD Cowen Adjusts Price Target on Ocular Therapeutix to $11 From $8, Maintains Market Perform Rating	MT
24-03-12	JMP Securities Adjusts Ocular Therapeutix's Price Target to $24 From $12, Maintains Market Outperform Rating	MT
24-02-26	Piper Sandler Adjusts Ocular Therapeutix Price Target to $15 From $10, Maintains Overweight Rating	MT
23-06-13	HC Wainwright Adjusts Ocular Therapeutix Price Target to $12 From $10, Maintains Buy Rating	MT
23-05-09	HC Wainwright Adjusts Price Target on Ocular Therapeutix to $10 From $11, Maintains Buy Rating	MT
23-05-09	JMP Securities Adjusts Price Target on Ocular Therapeutix to $12 From $11, Keeps Market Outperform Rating	MT
23-04-21	Baird Initiates Ocular Therapeutix at Outperform With $18 Price Target	MT
23-03-07	JMP Securities Adjusts Price Target on Ocular Therapeutix to $11 From $12, Maintains Market Outperform Rating	MT
23-02-14	HC Wainwright Adjusts Price Target on Ocular Therapeutix to $11 From $9, Maintains Buy Rating	MT
23-01-09	JMP Securities Adjusts Price Target on Ocular Therapeutix's to $12 From $25, Maintains Market Outperform Rating	MT
22-11-08	Raymond James Adjusts Price Target on Ocular Therapeutix to $14 From $29, Maintains Strong Buy Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	OCULAR THERAPEUTIX, INC.					+161.5%
	ELI LILLY AND COMPANY					+11.96%
	JOHNSON & JOHNSON					+1.66%
	ABBVIE INC.					+8.26%
	ROCHE HOLDING AG					+3.24%
	NOVARTIS AG					+0.76%
	ASTRAZENECA PLC					+31.03%
	AMGEN INC.					-10.16%
	NOVO NORDISK A/S					+4.82%
	GILEAD SCIENCES, INC.					+8.05%
	Average					+22.11%
	Weighted average by Cap.					+7.35%